Prevnar
Revenue rises at Pfizer as Ibrance and Xeljanz beat sales expectations
August 2, 2016Research and Development, Sales and Marketing 2016, Pfizer, Prevnar, Q2, Xeljanz, ibrance, results
Pfizer has published its Q2 results, which show revenues rising 11% with new drugs helping to drive the growth and …
Lipitor competition holds Pfizer back
July 31, 2013Sales and Marketing Lipitor, Pfizer, Prevnar, Q2
Pfizer’s revenues in the second quarter of 2013 fell 7% year-on-year, in part due to the loss of patent in …
Pfizer stumbles in third quarter
November 2, 2012Research and Development, Sales and Marketing Ian Read, Lipitor, Pfizer, Prevnar, Q3
Pfizer has experienced a worse than expected third quarter, due to disappointing sales of paediatric vaccine Prevnar and a surprise …
Lipitor loss continues to hit Pfizer sales
July 31, 2012Sales and Marketing Enbrel, Lipitor, Pfizer, Prevnar, Q2
Pfizer has posted a loss in revenue for the second quarter as the firm continues to feel the impact of …
Prevnar and Lyrica lift Pfizer results
November 1, 2011Research and Development, Sales and Marketing Lipitor, Lyrica, Pfizer, Prevnar, patent expiry
Strong sales of Lyrica and its Prevnar vaccines coupled with favourable exchange rates have helped Pfizer deliver a strong quarter. …
Latest content
Five Facts about cardiovascular disease
August 9, 2026
